HBIO Iron Condor Strategy
HBIO (Harvard Bioscience, Inc.), in the Healthcare sector, (Medical - Instruments & Supplies industry), listed on NASDAQ.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
HBIO (Harvard Bioscience, Inc.) trades in the Healthcare sector, specifically Medical - Instruments & Supplies, with a market capitalization of approximately $27.8M, a beta of 1.49 versus the broader market, a 52-week range of 3.8-9.4, average daily share volume of 22K, a public-listing history dating back to 2000, approximately 328 full-time employees. These structural characteristics shape how HBIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.49 indicates HBIO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a iron condor on HBIO?
An iron condor sells a call spread and a put spread at strikes outside spot, collecting net premium that is kept if the underlying stays inside the inner short strikes.
HBIO snapshot
As of August 14, 2026, spot at $5.99, ATM IV 37.10%, IV rank 3.18%, expected move 10.64%. The iron condor on HBIO below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 7-day expiry.
Why this iron condor structure on HBIO specifically: HBIO IV at 37.10% is on the cheap side of its 1-year range, which means a premium-selling HBIO iron condor collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 10.64% (roughly $0.64 on the underlying). The 7-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated HBIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on HBIO should anchor to the underlying notional of $5.99 per share and to the trader's directional view on HBIO stock.
HBIO iron condor setup
The HBIO iron condor below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With HBIO at $5.99 on that close, the first option leg uses a $6.29 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed HBIO chain at a 7-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 HBIO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Call | $6.29 | N/A |
| Buy 1 | Call | $6.59 | N/A |
| Sell 1 | Put | $5.69 | N/A |
| Buy 1 | Put | $5.39 | N/A |
HBIO iron condor risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the net credit times 100 inside the inner strikes; max loss equals wing width minus credit times 100. Two breakevens at inner strikes plus and minus the credit.
HBIO iron condor payoff curve
Modeled P&L at expiration across a range of underlying prices for the iron condor on HBIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use iron condor on HBIO
Iron condors on HBIO are a delta-neutral premium-collection structure that profits if HBIO stock stays inside the inner short strikes; short strikes typically sit near 1 standard deviation from spot.
HBIO thesis for this iron condor
The market-implied 1-standard-deviation range for HBIO extends from approximately $5.35 on the downside to $6.63 on the upside. A HBIO iron condor is a delta-neutral premium-collection structure that pays off when HBIO stays inside the inner short strikes through expiration; the wing width should reflect the trader's tolerance for the maximum loss scenario where the underlying breaches an outer strike. Current HBIO IV rank near 3.18% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on HBIO at 37.10%. As a Healthcare name, HBIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to HBIO-specific events.
HBIO iron condor positions are structurally neutral / range-bound; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. HBIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move HBIO alongside the broader basket even when HBIO-specific fundamentals are unchanged. Short-premium structures like a iron condor on HBIO carry tail risk when realized volatility exceeds the implied move; review historical HBIO earnings reactions and macro stress periods before sizing. Always rebuild the position from current HBIO chain quotes before placing a trade.
Frequently asked questions
- What is a iron condor on HBIO?
- A iron condor on HBIO is the iron condor strategy applied to HBIO (stock). The strategy is structurally neutral / range-bound: An iron condor sells a call spread and a put spread at strikes outside spot, collecting net premium that is kept if the underlying stays inside the inner short strikes. With HBIO stock at $5.99 on the most recent close, the strikes shown on this page are snapped to the nearest listed HBIO chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are HBIO iron condor max profit and max loss calculated?
- Max profit equals the net credit times 100 inside the inner strikes; max loss equals wing width minus credit times 100. Two breakevens at inner strikes plus and minus the credit. For the HBIO iron condor priced from the end-of-day chain at a 30-day expiry (ATM IV 37.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a HBIO iron condor?
- The breakeven for the HBIO iron condor priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The HBIO market-implied 1-standard-deviation expected move in the same options snapshot is approximately 10.64%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a iron condor on HBIO?
- Iron condors on HBIO are a delta-neutral premium-collection structure that profits if HBIO stock stays inside the inner short strikes; short strikes typically sit near 1 standard deviation from spot.
- How does current HBIO implied volatility affect this iron condor?
- HBIO ATM IV is at 37.10% with IV rank near 3.18%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.